Back to top

Image: Bigstock

Falling Earnings Estimates Signal Weakness Ahead for Eagle Pharmaceuticals (EGRX)

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Eagle Pharmaceuticals, Inc. (EGRX - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in EGRX.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 2 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from $4.39 a share a month ago to its current level of $3.69.

Also, for the current quarter, Eagle Pharmaceuticals has seen 2 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to $2.24 a share from $2.93 over the past 30 days.    

The stock also has seen some pretty dismal trading lately, as the share price has dropped 20.4% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical sector, you may instead consider a better-ranked stock - Aceto Corporation (ACET - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?

Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Adicet Bio, Inc. (ACET) - free report >>

Eagle Pharmaceuticals, Inc. (EGRX) - free report >>

Published in